Related Experiment Video
Updated: Dec 23, 2025
06:36
PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP
Published on: April 9, 2013
22.0K
QR 678 & QR678 Neo Vs PRP-A randomised, comparative, prospective study
Rinky Kapoor1, Debraj Shome2, Sapna Vadera2
1Department of Dermatology, Cosmetic Dermatology & Dermato-Surgery, The Esthetic Clinics, Mumbai, India.
Journal of Cosmetic Dermatology
|April 26, 2020
Summary
QR678 therapy significantly reduced hair fall and improved hair density in men with Androgenetic Alopecia compared to platelet-rich plasma (PRP). This therapy offers a more beneficial treatment for male pattern hair loss.
Area of Science:
- Dermatology
- Regenerative Medicine
Background:
- Androgenetic Alopecia (AGA) is a common cause of progressive hair thinning in men and women.
- Hair loss significantly impacts an individual's self-esteem and social well-being.
Purpose of the Study:
- To compare the efficacy of QR678 therapy against platelet-rich plasma (PRP) for treating male Androgenetic Alopecia.
- To evaluate treatment outcomes for male pattern hair loss using QR678 and PRP.
Main Methods:
- A prospective, single-blind study involving 50 patients divided into two groups.
- Group A received intradermal injections of QR678 formulations, while Group B received PRP.
- Hair assessments included hair pull tests, video microscopy, photographic evaluation, and patient questionnaires over a 1-year follow-up.
Main Results:
- QR678 therapy achieved a 100% reduction in hair fall within 6 months, sustained for 1 year.
- Video microscopy revealed significant improvements in hair density, terminal hair, vellus hair, and shaft diameter in the QR678 group (P < .005).
- QR678 and QR678 Neo formulations demonstrated equivalent efficacy.
Conclusions:
- QR678, a bioengineered formulation, is more beneficial for male Androgenetic Alopecia than PRP.
- Further comparative studies with long-term follow-up are recommended to expand knowledge on QR678 and PRP treatments.
